Zoetis has announced the European launch of Simparica Trio (sarolaner/moxidectin/pyrantel), a once-monthly ecto- and endoparasticide for dogs.

The chewable, prescription-only tablet contains sarolaner, which kills fleas and ticks; moxidectin, for the prevention of heartworm, lungworm disease and for the treatment of some intestinal worms; and pyrantel embonate, for the treatment of gastrointestinal nematodes (hookworms and roundworms). 

Professor Tim Geary, BSc PhD, Professor Emeritus, Institute of Parasitology, McGill University, Canada, and Professor, School of Biological Sciences, Queen’s University, Belfast, a consultant to Zoetis, said: “Serious diseases that are preventable and of increasing prevalence threaten dogs in Canada and Europe. Simparica Trio today offers a better solution to preventing and controlling these parasites against the concern of their increasing prevalence."

Rob Kelly, President, International Operations at Zoetis said: "With Simparica Trio, we bring to market an advanced parasiticide solution, helping to deliver improved client satisfaction and patient protection.

"Thanks to its broad spectrum, Simparica Trio helps veterinarians and dog owners provide more complete parasite coverage with a single-monthly chewable tablet. The broad spectrum of Simparica Trio minimises the potential risk of parasite protection gaps."

Simparica Trio is indicated for dogs from at least eight weeks of age and 1.25 kg and will be available in six tablet strengths for dogs of all sizes.

For more information about Simparica Trio and full prescribing information, visit www.zoetis.com.

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.